Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Eden Research Falls 3.3% — Is the Market Questioning the Next Leg of Growth?

Eden Research, Britain’s only listed pure-play biopesticide developer, has just banked a run of fresh regulatory wins across Europe and North Africa. Yet the AIM tiddler’s shares have drifted lower, leaving investors to weigh a widening product pipeline against the reality of aBusinessthat still …

Ankur Sharma | 18 August 2026

What Is Driving AstraZeneca Shares Higher as Positive Cancer Data, Pipeline Progress and the $80 Billion Sales Target Stay in Focus?

AstraZeneca shares gained0.87% on 17 August 2026, despite the pharmaceutical company announcing the discontinuation of a major late-stage lung-cancer trial.

Ankur Sharma | 18 August 2026

Why Is Halma LSE:HLMA Stock Rising 0.43% as Safety, Healthcare and Environmental Technology Demand Remains Strong?

Halma shares gained0.43% on 17 August 2026, extending investor interest in one of the UK's most consistent long-term growth companies.

Ankur Sharma | 18 August 2026

Redx Pharma in Focus: Can RXC008 and Zelasudil Unlock the Next Phase of Growth?

Redx Pharma remains an important name within the UK biotechnology landscape because of its focus onfibrotic disease, an area with significant unmet medical needs.

Ankur Sharma | 18 August 2026

Could GSK Shares Be Heading Higher as Strong Specialty Medicines and Vaccine Growth Boost the Outlook?

GSK shares rose1.87% to approximately £18.52 on 17 August 2026, making the pharmaceutical company one of the stronger performers among major UK healthcare names during the session.

Ankur Sharma | 18 August 2026

Could ConvaTec Stock Be Building Momentum as Wound Care, Ostomy and Infusion Products Continue to Gain Share?

ConvaTec shares gained1.05% on 17 August 2026, placing LSE:CTEC among the stronger healthcare names in the market session.

Ankur Sharma | 18 August 2026

ImmuPharma Tumbles 18% — Is Investor Patience Finally Running Out?

ImmuPharma (LSE:IMM) has once again reminded shareholders how violently a micro-cap drug developer can move. The stock, which trades in low single-digit pence, gave back a chunk of its recent gains in a sharp one-day drop that a screener flagged at roughly 18%. That …

Divya Sood | 17 August 2026

ProBiotix Health Falls 8.3% — Has the Market Lost Its Appetite for the Story?

ProBiotix Health (LSE:PBX) has drifted lower in recent sessions, with a single-day screener snapshot pointing to a fall of roughly 8.3%. That kind of move looks dramatic in percentage terms, but it needs context: ProBiotix is a genuine micro-cap. The shares changed hands at …

Divya Sood | 17 August 2026

Why Did Oxford Biomedica PLC LSE:OXB Gain 1.75% as continued interest in gene and cell therapy manufacturing capacity?

Oxford Biomedica PLC — LSE:OXB gained1.75% on 17 August 2026, taking the shares to 495.50p.

Ishan Mudgal | 17 August 2026

LSE:FARN Rises 5.91% as Bexmarilimab Survival Data Strengthens Faron’s Cancer-Drug Story

Faron Pharmaceuticals has attracted renewed attention on17 August 2026, with LSE:FARN shares gaining5.91%.

Ankur Sharma | 17 August 2026
Support

Hi! How can we help you today?

Loading…